LIFCASUS Trademark

Trademark Overview

On Thursday, February 8, 2024, a trademark application was filed for LIFCASUS with the United States Patent and Trademark Office. The USPTO has given the LIFCASUS trademark a serial number of 98397734. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, March 18, 2025. This trademark is owned by Celgene Corporation. The LIFCASUS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
lifcasus

General Information

Serial Number98397734
Word MarkLIFCASUS
Filing DateThursday, February 8, 2024
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, March 18, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 21, 2025

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical and biological preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use, namely, for the treatment of neuropsychiatric disorders; Pharmaceutical preparations for human use, namely, therapeutic radiopharmaceutical preparations for the treatment of cancer and solid tumors, diagnostic radiopharmaceutical preparations, diagnostic agents, preparations and substances for medical purposes; Pharmaceutical preparations for human use, namely, radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer, radio-isotope markers for therapeutic or diagnostic use.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, February 8, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543
Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Trademark Events

Event DateEvent Description
Thursday, February 8, 2024NEW APPLICATION ENTERED
Friday, June 7, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, August 28, 2024ASSIGNED TO EXAMINER
Tuesday, September 3, 2024NON-FINAL ACTION WRITTEN
Tuesday, September 3, 2024NON-FINAL ACTION E-MAILED
Tuesday, September 3, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, December 3, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 3, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, December 3, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, December 30, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 15, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 21, 2025PUBLISHED FOR OPPOSITION
Tuesday, January 21, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 18, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT

Related Keywords

lifcasus diseases pharmaceutical human preparations anti system disease cancer disorders namely